רווח למניה בשנים עשר החודשים האחרונים: Catalyst Pharma (CPRX)

Catalyst Pharmaceuticals (CPRX) ensures a steady capital inflow through its monopoly status in the therapy of rare syndromes. This 12-month EPS trend chart visualizes this success, where 1.73 defines the current value of the metric. Revenues are based on exclusive sales of orphan drugs in the US, while drug synthesis is fully outsourced to third-party contractors via strict SLA agreements.

Amid inflationary pressure, business resilience to external shocks is determined by the ability to generate real cash flow per share. The robotization of orphan drug logistics via third-party capacities for Catalyst Pharmaceuticals (CPRX) reduces costs, which is reflected in the trailing 12-month earnings per share trend, measuring annual net income with daily recalculations to capture fundamental reversals prior to official reports.